AbbVie Inc. (ABBV)
3 Fabulous Dividend Stocks to Buy in February
February is the shortest month, but that doesn't mean income investors don't have much time to find great stocks. Three Motley Fool contributors believe they have identified fabulous dividend stocks to buy this month.
3 Dividend Stocks to Double Up on Right Now
What's better than a good thing? More of a good thing.
These 2 Dividend Stocks Are Absolute Bargains Right Now
Dividend stocks are great for many reasons, not least because any company that can sustain growing payouts for a long time likely has a strong underlying business. It's even better to invest in excellent income stocks when they seem to be trading at attractive valuations, which isn't always easy to find since such corporations are in high demand.
Income Strategy: I'm Stashing Cash Into These Wonderful Dividends
Inflation can be countered by investing in income-generating assets like consumer staples, energy, and pharmaceuticals, which provide essential products and reliable dividends. In this article, I highlight two such names that offer robust payouts which are well-covered by earnings. Both carry moat-worthy business models and have strong pipelines that support potential for robust total returns.
US FDA approves AbbVie's treatment for intra-abdominal infections
AbbVie said that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections on Friday.
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
3 Top AI-Powered Biotech Stocks to Buy in February
Artificial intelligence (AI) is transforming various industries as a major investing theme in 2025. The technology's ability to automate complex workflows and enhance productivity is seen as a game-changer for the next generation of innovation.
AbbVie Rises 8% Since Q4 Earnings: Buy, Hold or Sell the Stock?
Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.
Idexx Stock, AbbVie, and Molina Buck Downward Tariff Trend. These Are Today's Top S&P 500 Performers.
Idexx Laboratories, AbbVie, and Molina Healthcare trade higher on a down day for Wall Street.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Buy, Sell, Or Hold ABBV Stock At $185?
AbbVie (NYSE: ABBV) recently released its Q4 results, with revenues and earnings comfortably above the street estimates. It reported sales of $15.1 billion and adjusted earnings of $2.16 per share, compared to the consensus estimates of $14.8 billion and $2.11, respectively.
2 Undervalued Dividend Stocks Ready For A Major Comeback
The economy is mixed - strong in some sectors, weak in others. I see value in cyclical stocks and healthcare, both lagging but poised for growth. One pick is a cyclical turnaround story with strong recovery potential. The other is a high-yield healthcare gem with anti-cyclical resilience. Both stocks offer market-beating potential, solid dividends, and long-term growth. They're perfect for balancing risk and reward in today's uncertain economy.
